作者
Marcelo Augusto Duarte Silveira, David De Jong, Andresa Aparecida Berretta, Erica Batista dos Santos Galvao, Juliana Caldas Ribeiro, Thiago Cerqueira-Silva, Thais Chaves Amorim, Luis Filipe Miranda Rebelo da Conceicao, Marcel Miranda Dantas Gomes, Mauricio Brito Teixeira, Sergio Pinto de Souza, Marcele Helena Celestino Alves Dos Santos, Raissa Lanna Araujo San Martin, Márcio de Oliveira Silva, Monique Lírio, Lis Moreno, Julio Cezar Miranda Sampaio, Renata Mendonça, Silviana Salles Ultchak, Fabio Santos Amorim, Joao Gabriel Rosa Ramos, Paulo Benigno Pena Batista, Suzete Nascimento Farias da Guarda, Ana Verena Almeida Mendes, Rogerio da Hora Passos
发表日期
2021/6/1
期刊
Biomedicine & Pharmacotherapy
卷号
138
页码范围
111526
出版商
Elsevier Masson
简介
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and inflammatory phenomena. Though various therapeutic possibilities have been tested against coronavirus disease 2019 (COVID-19), the most adequate treatment has not yet been established. Propolis is a natural product with considerable evidence of immunoregulatory and anti-inflammatory activities, and experimental data point to potential against viral targets. We hypothesized that propolis can reduce the negative effects of COVID-19.
Methods
In a randomized, controlled, open-label, single-center trial, hospitalized adult COVID-19 patients were treated with a standardized green propolis extract (EPP-AF®️) as an adjunct therapy. Patients were allocated to receive standard care plus an oral dose of 400 mg or 800 mg/day of green propolis for seven days, or standard care alone. Standard care …
学术搜索中的文章
MAD Silveira, D De Jong, AA Berretta… - Biomedicine & Pharmacotherapy, 2021